Table 1

Comparison of reported IRs of DVT and PE and the ratio of IR DVT/IR PE

	IRs	DVT	PE	IR DVT:IR PE
Tofacitinib
RA all tofacitinib cohort	5 mg constant	0.11	0.06	1.83
RA all tofacitinib cohort	10 mg constant	0.13	0.15	0.87
RA CV risk+	5 mg	0.34	0.25	1.36
RA CV risk+	10 mg	0.17	0.24	0.71
RA VTE risk+	5 mg	0.25	0.2	1.25
RA VTE risk+	10 mg	0.18	0.17	1.06
ENTRACTE	Etanercept	0.3	0.2	1.50
ENTRACTE	Tocilizumab	0.2	0.06	3.33
A3921133	5 mg	0.3	0.27	1.11
	10 mg	0.38	0.54	0.70
	TNF-i	0.18	0.09	2.00
PsO all tofacitinib cohort	5 mg average	0.06	0.13	0.46
PsO all tofacitinib cohort	10 mg average	0.06	0.09	0.67
PsA all tofacitinib cohort	5 mg average	0	0.08	0.00
PsA all tofacitinib cohort	10 mg average	0.13	0	ND
Ulcerative colitis	5 mg predominant	0.00	0.00	ND
Ulcerative colitis	10 mg predominant	0.05	0.21	0.24
Trial data (patients not enriched for ATE/VTE risk factors)
Baricitinib4
Extended data set	2 mg	0.6	0.2	3.00
Extended data set	4 mg	0.3	0.3	1.00
Upadacitinib23 (concurrent DVT/PE)
	Pooled PBO (0)	0	0,4	0.00
	MTX (0.3)	0.3	0.5	0.60
	Adalimumab (0))	0.2	0.9	0.22
	15 mg (0.2)	0.3	0.5	0.60
	30 mg (<0.1)	0.2	0.1	2.00

Data from Mease et al 5 and Sandborn et al 24 for the ulcerative colitis programme. Available data from long-term extension studies of baricitinib5 and the upadacitinib programme23 among patients not enriched for risk factors are shown for comparison.
CV, cardiovascular; DVT, deep vein thrombosis; IR, incidence rate; PBO, placebo; PE, pulmonary embolism; RA, rheumatoid arthritis; VTE, venous thromboembolic event.